ABT · 10-Q · 2026Q3 · Full report

Product Launch and Transition

ABBOTT LABORATORIES · 2026-11-04 · Importance 31 · Surprise 42

Abbott received several significant product approvals and launched new products in 2026. Libre Duo, a dual glucose-ketone biowearable sensor, received CE Mark and FDA approval, while the Amulet 360 left atrial appendage occluder received CE Mark. Abbott launched Similac 360 Total Care Made With Whole Milk in the U.S. and received FDA approval for the TactiFlex Duo ablation catheter, which delivers both pulsed field and radiofrequency energy. Abbott also launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for average-risk adults age 45 and older.

Key facts

• In May 2026 Abbott announced it secured CE Mark for Libre Duo, its dual glucose-ketone biowearable sensor. source
• In August 2026 Abbott announced U.S. FDA approval for Libre Duo, its dual glucose-ketone biowearable sensor. source
• In August 2026 Abbott received CE Mark for its Amulet 360 Left Atrial Appendage Occluder, designed to reduce stroke risk in patients with atrial fibrillation. source
• In August 2026 Abbott launched Similac 360 Total Care Made With Whole Milk in the U.S., a commercially sterile, ready-to-feed liquid infant formula. source
• In September 2026 Abbott announced FDA approval for the TactiFlex Duo Ablation Catheter, Sensor Enabled, which delivers pulsed field and radiofrequency energy to treat AFib. source
• In September 2026 Abbott launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults aged 45 and older at average risk. source
• In September 2026, Abbott completed the transfer of its Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories from Structural Heart to Electrophysiology, effective January 1, 2026. source
• Beginning in 2026, Abbott combined its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into Rapid and Molecular Diagnostics. source